-
41.发明申请公开(公告)号：US20110229561A1
公开(公告)日：2011-09-22
申请号：US13060109
申请日：2009-08-22
申请人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
发明人： Ritesh Kapoor , Munish Talwar , Sanjay Mate , Manoj Mashalkar , Girish Kumar Jain , Mandar Kodgule
IPC分类号： A61K31/277 , A61K9/20 , A61K9/48 , A61P25/16
CPC分类号： A61K9/2054 , A61K9/2027 , A61K9/209 , A61K9/28 , A61K31/197 , A61K31/198 , A61K31/277 , A61K2300/00
摘要： There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
摘要翻译： 提供了包含约200mg至约1000mg恩他卡朋或其盐，任选与其它药学上可接受的赋形剂的延长释放药物组合物。 本发明还提供了延长释放的药物组合物，其包含约30mg至约300mg左旋多巴，10mg至约100mg卡比多巴和200mg至约1000mg的恩他卡朋或其盐的三重组合，任选与其它药学上可接受的 赋形剂。 本发明还涉及这种组合物的制备方法。
-
公开(公告)号：US20110097414A1
公开(公告)日：2011-04-28
申请号：US12528627
申请日：2008-02-26
申请人： Roshan lal Sandal , Vikrant Thakkar , Ramakant Kashinath Gundu , Rahul Sudhakar Dabre , Narayanan Murali , Girish Kumar Jain
发明人： Roshan lal Sandal , Vikrant Thakkar , Ramakant Kashinath Gundu , Rahul Sudhakar Dabre , Narayanan Murali , Girish Kumar Jain
IPC分类号： A61K9/14 , A61K31/235
CPC分类号： A61K9/143 , A61K9/1635 , A61K9/1652 , A61K31/216
摘要： The present invention provides a pharmaceutical composition comprising adsorbate of fenofibrate or salt thereof or fenofibrate adsorbed on a pharmaceutically acceptable adsorbent and optionally one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions.
摘要翻译： 本发明提供药物组合物，其包含非诺贝特或其盐的吸附物或吸附在药学上可接受的吸附剂上的非诺贝特和任选的一种或多种药学上可接受的赋形剂。 本发明还涉及制备这种组合物的方法。
-
公开(公告)号：US20100285126A1
公开(公告)日：2010-11-11
申请号：US12671832
申请日：2008-08-01
IPC分类号： A61K9/28 , A61K31/216 , A61P7/00 , A61P3/06
CPC分类号： A61K31/216 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2059 , A61K9/2095
摘要： The invention relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more pharmaceutically acceptable vehicles. The invention also relates to pharmaceutical compositions comprising non-micronized fenofibrate with one or more cyclodextrin derivatives. The invention also relates to processes for the preparation of such compositions.
摘要翻译： 本发明涉及包含非微粉化非诺贝特与一种或多种药学上可接受的载体的药物组合物。 本发明还涉及包含非微粉化非诺贝特与一种或多种环糊精衍生物的药物组合物。 本发明还涉及制备这种组合物的方法。
-
44.发明申请Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa 失效包含恩他卡朋，左旋多巴和卡比多巴的药物组合物公开(公告)号：US20100129441A1
公开(公告)日：2010-05-27
申请号：US12447405
申请日：2007-10-25
申请人： Sudhir Goswami , Mahesh Rameshwar Kalantri , Asif Mohammad , Narayanan Murali , Girish Kumar Jain
发明人： Sudhir Goswami , Mahesh Rameshwar Kalantri , Asif Mohammad , Narayanan Murali , Girish Kumar Jain
IPC分类号： A61K9/48 , A61K31/195 , A61K9/20 , A61P25/16
CPC分类号： A61K47/38 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/5084 , A61K31/137 , A61K31/197 , A61K31/198 , A61K31/277 , A61K2300/00
摘要： The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions.
摘要翻译： 本发明涉及稳定的药物组合物，其包含恩他卡朋，左旋多巴和卡比多巴，或其药学上可接受的盐或水合物。 本发明还涉及制备这种组合物的方法。
-
公开(公告)号：US20090156631A1
公开(公告)日：2009-06-18
申请号：US11991361
申请日：2006-12-15
IPC分类号： A61K31/437 , A61P25/20
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/5084
摘要： The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.
摘要翻译： 本发明涉及根据单相和/或双相溶出曲线，唑吡旦或其药学上可接受的盐适于在预定时间段内释放唑吡坦的控释组合物。 本发明还涉及唑吡旦或其药学上可接受的盐的基于整体式基质的制剂。
-
公开(公告)号：US09358213B2
公开(公告)日：2016-06-07
申请号：US12595838
申请日：2008-04-19
CPC分类号： A61K9/2886 , A61K9/2027 , A61K9/2059 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K9/4891 , A61K9/5026 , A61K9/5047 , A61K9/5073 , A61K9/5078 , A61K31/381 , A61K47/585
摘要： The present invention relates to pharmaceutical compositions of duloxetine or pharmaceutically acceptable salts thereof, and processes for their preparation.
摘要翻译： 本发明涉及度洛西汀或其药学上可接受的盐的药物组合物及其制备方法。
-
公开(公告)号：US08999381B2
公开(公告)日：2015-04-07
申请号：US12680335
申请日：2008-09-27
IPC分类号： A61K9/14 , A61K9/48 , A61K9/107 , A61K31/222 , A61K47/44
CPC分类号： A61K31/235 , A61K9/1075 , A61K9/4825 , A61K9/4858 , A61K31/222 , A61K47/44
摘要： The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions.
-
公开(公告)号：US08962016B2
公开(公告)日：2015-02-24
申请号：US12954644
申请日：2010-11-25
申请人： Prashant Manohar Mandaogade , Venkatesh Madhavacharya Joshi , Saurabh Srivastava , Vinayak Dinkar Kadam , Girish Kumar Jain
发明人： Prashant Manohar Mandaogade , Venkatesh Madhavacharya Joshi , Saurabh Srivastava , Vinayak Dinkar Kadam , Girish Kumar Jain
IPC分类号： A61K9/48 , A61K9/00 , A61K9/20 , A61K9/50 , A61K31/435 , A61K31/138 , A61K31/554 , A61K31/18
CPC分类号： A61K31/138 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/5047 , A61K9/5078
摘要： The present invention relates to extended release dosage forms of metoprolol or salts thereof comprising a water insoluble and non-swellable inert core and one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of an inert core and extended release dosage forms.
摘要翻译： 本发明涉及美托洛尔或其盐的延长释放剂型，其包含水不溶性和不可溶胀的惰性核心和一种或多种药学上可接受的赋形剂。 本发明还涉及制备惰性核心和延长释放剂型的方法。
-
公开(公告)号：US20140302125A1
公开(公告)日：2014-10-09
申请号：US14240380
申请日：2012-08-23
IPC分类号： A61K31/4418 , A61K31/41 , A61K31/40 , A61K31/138
CPC分类号： A61K31/4418 , A61K31/138 , A61K31/40 , A61K31/41 , A61K45/06 , A61K31/135 , A61K2300/00 , A61K31/4422
摘要： There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient.
摘要翻译： 提供了用于治疗心血管疾病的每日一次治疗协同药物剂型，其中剂型包括延长释放形式的美托洛尔和一种或多种钙通道阻滞剂，血管紧张素II受体阻断剂或血管紧张素转化酶的固定剂量组合 酶抑制剂以及一种或多种速率控制赋形剂。
-
公开(公告)号：US08846084B2
公开(公告)日：2014-09-30
申请号：US11991361
申请日：2006-12-15
CPC分类号： A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/209 , A61K9/5084
摘要： The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.
摘要翻译： 本发明涉及根据单相和/或双相溶出曲线，唑吡旦或其药学上可接受的盐适于在预定时间段内释放唑吡坦的控释组合物。 本发明还涉及唑吡旦或其药学上可接受的盐的基于整体式基质的制剂。
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.071 秒)
